Abstract
Despite concern that a higher risk of side effects might alter the net risk/benefit ratio for neurohormonal therapy, which includes beta-blockers and ACEi/ARB/ARNI in older HFrEF patients, the benefits of neurohormonal therapy do not decrease with increasing age. See the related article by Gilstrap, pages 2811-2820.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
